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ABSTRACT
Optimal use of antibiotics is a key component of the management of sepsis. The purpose of this study
was to develop a modification of the time-to-positivity (Tpos) assay for use in the acute management of
septic patients. Initial laboratory experiments, followed by ex-vivo validation and pilot studies, were
performed with a small number of healthy human volunteers and 46 septic patients on a general
intensive care unit, chosen on the basis of their antibiotic regimen. The study demonstrated that the Tpos
assay could be used as a surrogate for antimicrobial activity, and provided preliminary data to
demonstrate how this approach might be used to monitor the efficacy of antibiotic therapy in septic
patients. The Tpos assay might offer a quick and convenient way to improve the efficacy of antibiotic
therapy in septic patients, and further prospective large-scale studies are now warranted.
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INTRODUCTION
Bacterial sepsis remains a leading cause of mor-
bidity, with a particularly high mortality rate
among patients in intensive care units (ICUs), and
also constitutes an enormous healthcare cost.
Antibiotic therapy is a cornerstone of manage-
ment [1], but until there is microbiological evi-
dence of infection, most patients are initially
treated empirically. A considerable body of evi-
dence has shown that appropriate antibiotic treat-
ment (i.e., a regimen that is active against the
causative pathogen) is associated with a signifi-
cantly improved outcome [2,3]. The quicker such
a regimen is employed, the better the outcome is
likely to be. However, conventional microbiologi-
cal methods typically require that cultures be
incubated for 12–18 h before a preliminary diag-
nosis can be made. Hence, a test that would
provide evidence of the adequacy of antibiotic
therapy in a shorter period would potentially be
of clinical value.
‘Time-to-positivity’ (Tpos) assays depend on the
ability of automated blood culture detection
systems to ‘flag’ a sample as soon as it is
registered as positive. Whereas conventional
blood culture bottles are inspected visually for
evidence of bacterial growth perhaps once or
twice during initial overnight incubation, the
automated systems allow very frequent (some-
times continuous) monitoring, and allow detec-
tion of a positive sample much more quickly.
Because the density of the inoculum is one of the
key variables that determines how quickly a
sample will register positive, several investigators
have explored the notion that Tpos could be used
as a diagnostic test, particularly for intravascular
catheter-associated infections [4,5].
The present study hypothesised that, if a serum
sample of a patient being treated for sepsis was
inoculated with one or more standard organisms,
the Tpos could be used as a surrogate marker of
total antibacterial activity in the sample, and
hence the adequacy of treatment. In simple terms,
it might be expected that the longer the Tpos, the
greater the antimicrobial activity. This article
describes and validates the method, and shows
how it could be applied to the management of
septic patients in an ICU.
Corresponding author and reprint requests: J. Cohen, Brighton
& Sussex Medical School, Falmer, Brighton BN1 9PX, UK
E-mail: j.cohen@bsms.ac.uk
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
MATERIALS AND METHODS
Bacterial strains, serum and inoculum preparation
This study used clinical isolates from blood cultures of septic
patients in an ICU: Staphylococcus aureus (methicillin-resistant)
(BC 2985), Escherichia coli (BC 3164) and Pseudomonas aeruginosa
(BC 6119). MICs were determined with the Etest method [6].
One antibiotic was tested for each isolate: vancomycin (Lilly,
Basingstoke, UK) against S. aureus; gentamicin (Roche Diag-
nostics, Lewes, UK) against E. coli; and imipenem (MSD,
Hoddesdon, UK) against P. aeruginosa. Normal human serum
was obtained from a small number of healthy adult volunteers.
The sera were stored as aliquots at ) 20C.
A standardised inoculum of 0.5 · 106 to 1 · 106 CFU was
prepared by inoculating four to five colonies of a pure culture
into 5 mL of Mueller–Hinton (MH) broth. The broth was
incubated for 2 h at 35C until it was visibly turbid (in mid-
logarithmic phase). The inoculum size was measured with the
Miles and Misra method [7].
In-vitro studies
In order to determine whether there was a direct quantitative
relationship between the number of bacteria in a blood culture
and the Tpos, tubes containing 1.8 mL of pooled healthy human
serum were inoculated with 0.2 mL of a series of ten-fold
dilutions of the standardised inoculum of each of the bacteria
in turn. The inoculated sera were transferred into BacT ⁄
ALERT bottles (bioMe´rieux, Durham, NC, USA) for aerobic
incubation.
In order to determine whether the Tpos was influenced by
the addition of antibiotics, tubes containing 1 mL of normal
human serum and a range of antibiotic concentrations (cov-
ering the normal therapeutic levels) were inoculated with
1 mL of MH broth containing 0.5 · 106 to 1 · 106 CFU for each
antibiotic ⁄ bacterium pair, and then transferred to BacT ⁄
ALERT bottles for aerobic incubation.
Ex-vivo studies
In order to determine the effect on the TPOS as the antibiotic was
eliminated, a single therapeutic dose of antibiotic was injected
intravenously into a healthy volunteer and serial blood
samples were taken at various time-points thereafter. Serum
was separated from the samples, and 1-mL aliquots were
inoculated with 1 mL of MH broth containing 0.5 · 106 to
1 · 106 CFU; the mixtures were then transferred into BacT ⁄
ALERT bottles for aerobic incubation.
In order to estimate the variability of the Tpos in clinical
samples from septic patients, random blood samples were
taken from 46 patients in the ICU who were being treated
with the selected antibiotics. Serum was separated from the
samples, and 1-mL aliquots were inoculated with 1 mL of
MH broth containing 0.5 · 106 to 1 · 106 CFU; the mixtures
were then transferred into BacT ⁄ALERT bottles for aerobic
incubation. The microorganism tested was selected to match
the antibiotic that the patient was receiving. A positive
control (microorganism plus a known concentration of
antibiotic) and a negative control (microorganism alone) were
included.
All experiments involving healthy human subjects or
patients were carried out with the approval of the Hammer-
smith Hospitals Trust Research Ethics Committee.
Statistical methods
Data were entered into the SigmaStat program (SPSS Inc.,
Chicago, IL, USA), and linear correlation coefficients were
computed. Where necessary, the values were log-transformed
before calculation.
RESULTS
The MIC of vancomycin for the S. aureus isolate
was 4 mg ⁄L, the MIC of gentamicin for the E. coli
isolate was 1 mg ⁄L, and the MIC of imipenem for
the P. aeruginosa isolate was 4 mg ⁄L.
There was a linear correlation between the
number of CFU inoculated into healthy human
serum and the Tpos in the Bact ⁄Alert system,
even at very low numbers (0.93 · 101 CFU)
(Fig. 1). This relationship was consistent and
reproducible for each antibiotic–microorganism
combination tested. There was a good correlation
between the Tpos and increasing concentrations
of antibiotic in healthy human serum inoculated
with a fixed number of bacteria (Fig. 2). How-
ever, for the combinations S. aureus–vancomycin
and P. aeruginosa–imipenem, the relationship
was not seen for the lowest concentrations of
antibiotic.
The natural pharmacokinetic decay of antibiotic
concentration in the serum of a healthy subject
was reflected in the Tpos when the serum was
inoculated with a fixed number of bacteria. As the
antibiotic was cleared, the Tpos shortened (Fig. 3),
demonstrating that the Tpos could be used as a
surrogate for antimicrobial activity.
Random serum samples, obtained from patients
in the ICU, that were spiked with test organisms
showed a range of Tpos values. The negative
controls provided the baseline, and the positive
controls fell within the range of the results from
patients. There was sufficient variability in the
Tpos values in clinical samples from patients
receiving antibiotic therapy to ensure discrimin-
ation between high and low values, within the
limits of the assay (Fig. 4).
DISCUSSION
The importance of optimising antibiotic therapy
in septic patients is widely accepted. A large
number of clinical investigations have shown
that the mortality rate in patients treated with
appropriate antibiotics is lower than in those not
receiving appropriate antibiotics [3,8]. In this
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context, ‘appropriate’ is usually taken to mean
an antibiotic that is active in vitro against the
organism causing the infection. However, truly
appropriate antibiotic therapy goes beyond sim-
ple in-vitro activity, since it is also dependent on
pharmacokinetic and pharmacodynamic consid-
erations that relate to tissue distribution and the
activity of an antibiotic in a clinical environment
that is often far removed from the ideal condi-
tions in which pharmacological studies are per-
formed.
The serum bactericidal assay (or serum bacte-
ricidal test, or titre; SBT) ought to be the ideal way
to assess the appropriateness of antibiotic ther-
apy, since it is one of the few ex-vivo tests
performed in the clinical laboratory that reflects
the interaction of the isolated pathogen, the
antimicrobial agent and the patient. However,
most investigators regard the SBT as imprecise
and time-consuming, and because quality control
schemes have shown it to have poor reproduci-
bility, it has generally fallen into disuse.
The present article describes a novel approach
that extends the principle of Tpos assays from use
in diagnosis to use in patient management. The
key findings are (1) that Tpos correlates directly
with antimicrobial activity in serum, both in-vitro
and ex-vivo, and (2) that measurements of Tpos in
septic patients in an ICU show considerable
differences, suggesting that there is indeed signi-
ficant variability in the antimicrobial activity of
common antibiotic regimens, and hence an oppor-
tunity to use this method to optimise therapy in
these very ill patients.
A number of potential limitations to this
approach must be recognised. The method
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Fig. 1. Correlation between the time-to-positivity (h) in the
BacT ⁄Alert system and the number of CFU inoculated into
healthy human serum for three different microorganisms
(methicillin-resistant Staphylococcus aureus (a), Pseudomonas
aeruginosa (b), and Escherichia coli (c)). The data are
representative of three similar experiments for each micro-
organism, all of which gave identical results. (a) r = 0.71,
p < 0.049. (b) r = 0.66, p < 0.001. (c) r = 0.70, p < 0.055.
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involves the assumption that the patient does
indeed have a bacterial infection that requires
antibiotic therapy. If the patient is not infected,
then the test will yield a ‘false-positive’ result, in
that there may well be antibiotic activity in the
patient’s serum, directed against the control
organism. Similarly, the result will be misleading
if the patient is infected with a fungus. Both of
these limitations reflect a general clinical require-
ment that a test must be interpreted in the context
of a correct underlying diagnosis. It also needs to
be acknowledged that, at present, this approach
would only be valid for the c. 20–25% of septic
patients who are bacteraemic. Future studies
should evaluate patients with a focus at a differ-
ent site.
A second potential problem is that the bacteri-
cidal activity demonstrated against the control
organism might be very different to that against
the actual infecting pathogen. The control organ-
isms used were chosen to represent typical ICU
pathogens, but the confidence with which a result
can be extrapolated from a control organism to a
patient’s isolate remains unknown until further,
more extensive experience has been gained. An
alternative approach would involve performing
the assay with the patient’s isolate as soon as it is
available. This would have the advantage of
greater specificity, but the disadvantage of intro-
ducing a delay before the test could be performed.
Future studies should compare these two approa-
ches to determine which yields the more useful
results.
Finally, a concern was that the method would
not be sufficiently robust or reproducible to be
clinically useful, or that the degree of variability
in the Tpos in patients in an ICU would be
insufficient to make measurement worthwhile.
However, the initial data suggest that the results
are reproducible and that there are sufficiently
large differences in the clinical measurements to
justify a prospective study comparing Tpos with
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Fig. 2. Time-to-positivity (h) in the BacT ⁄Alert system for
the three microorganisms studied when a fixed number of
CFU was inoculated into healthy human serum containing
different levels of the selected antibiotic. The data are
representative of three similar experiments for each micro-
organism, all of which gave identical results. (a) Vanco-
mycin vs. methicillin-resistant Staphylococcus aureus;
r = 0.95, p < 0.001. (b) Imipenem vs. Pseudomonas aerugi-
nosa; r = 0.66, p < 0.001. (c) Gentamicin vs. Escherichia coli;
r = 0.94, p < 0.001.
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clinical outcomes. Preliminary data (not shown)
suggest that there is indeed a correlation between
Tpos and length of stay in the ICU.
Optimising antibiotic therapy for septic
patients in the ICU is an important goal. The
method described in this paper is attractive
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Fig. 3. Time-to-positivity (h) in serial blood samples obtained after infusion of a single dose of (a) vancomycin or (b)
imipenem in a healthy volunteer. Each sample was inoculated with a fixed number of CFU (methicillin-resistant
Staphylococcus aureus for vancomycin, and Pseudomonas aeruginosa for imipenem).
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Fig. 4. Time-to-positivity (h) in random blood samples
received from patients in the intensive care unit who
received the selected antibiotics as part of their therapy. (a)
Time-to-positivity in 20 patients who received vancomy-
cin. (b) Time-to-positivity in 13 patients who received
imipenem. (c) Time-to-positivity in 13 patients who
received gentamicin. c+, positive control; c–, negative
control.
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because it is less technically demanding than the
standard SBT assay, and requires only one addi-
tional blood sample. Further studies are warran-
ted to establish whether this approach may be of
value in monitoring antibiotic therapy in individ-
ual patients, and ⁄ or as a method to evaluate the
efficacy of various antibiotic strategies in defined
patient groups.
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